{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:18:53Z","timestamp":1789611533015,"version":"build-2803163510"},"reference-count":46,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Invasive mould diseases are associated with high morbidity, mortality and economic impact. Its treatment is often started prior to differential pathogen diagnosis. Isavuconazole is approved for treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) when amphotericin\u2010B is not indicated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To estimate the cost\u2010effectiveness of isavuconazole vs voriconazole for the treatment of adult patients with possible IA prior to differential pathogen diagnosis, in Spain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A decision tree analysis was performed using the Spanish Healthcare System perspective. Among all patients with possible IA, it was considered that 7.81% actually had IM. Costs for laboratory analysis, management of adverse events, hospitalisation and drugs per patient, deaths and long\u2010term effects in life years (LYs) and quality\u2010adjusted LYs (QALYs) were considered. Efficacy data were obtained from clinical trials and utilities from the literature. Deterministic and probabilistic sensitivity analyses (PSA) were conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In patients with possible IA and when compared to voricanozole, isavuconazole showed an incremental cost of 4758.53\u20ac, besides an incremental effectiveness of +0.49 LYs and +0.41 QALYs per patient. The Incremental Cost Effectiveness Ratio was 9622.52\u20ac per LY gained and 11,734.79\u20ac per QALY gained. The higher cost of isavuconazole was due to drug acquisition. Main parameters influencing results were mortality, treatment duration and hospitalisation days. The PSA results showed that isavuconazole has a probability of being cost\u2010effective of 67.34%, being dominant in 24.00% of cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Isavuconazole is a cost\u2010effective treatment compared to voriconazole for patients with possible IA for a willingness to pay threshold of 25,000\u20ac per additional QALY.<\/jats:p><\/jats:sec>","DOI":"10.1111\/myc.13189","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T11:11:52Z","timestamp":1601377912000},"page":"66-77","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The cost\u2010effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain"],"prefix":"10.1111","volume":"64","author":[{"given":"Jos\u00e9 Ram\u00f3n","family":"Azanza","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Department Cl\u00ednica Universidad de Navarra Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[{"name":"Pharmacy Department Hospital del Mar Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital Cl\u00ednico Universitario de Salamanca Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-6540","authenticated-orcid":false,"given":"Pablo","family":"Rebollo","sequence":"additional","affiliation":[{"name":"Ingress\u2010health Oviedo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Peral","sequence":"additional","affiliation":[{"name":"Pharmacoeconomics Department Pfizer Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"L\u00f3pez\u2010Ib\u00e1\u00f1ez de Aldecoa","sequence":"additional","affiliation":[{"name":"Pharmacoeconomics Department Pfizer Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"L\u00f3pez\u2010G\u00f3mez","sequence":"additional","affiliation":[{"name":"Medical Department Pfizer Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2007.140087"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(02)00035-1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040057"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/432579"},{"issue":"4","key":"e_1_2_8_6_1","first-page":"378","article-title":"Treatment of invasive fungal infections in high\u2010risk haematological patients: what have we learnt in the past 10 years?","volume":"26","author":"Vallejo C","year":"2013","journal-title":"Rev Esp Quimioter"},{"key":"e_1_2_8_7_1","unstructured":"FDA.Briefing Document. Anti\u2010Infective Drugs Advisory Committee meeting. NDA 2\u20107\u2010501: Isavuconazol\u00ae (Isavuconazonium) for injection and NDA 207\u2013500 Isavuconazol\u00ae (Isavuconazonium) capsules. In:2015."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S122177"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179136"},{"key":"e_1_2_8_10_1","unstructured":"MSCBS.Registro de Actividad de Atenci\u00f3n Especializada Conjunto M\u00ednimo B\u00e1sico de Datos\u2010 Hospitalizaci\u00f3n RAE\u2010CMBD.2019;https:\/\/pestadistico.inteligenciadegestion.mscbs.es\/publicoSNS\/comun\/ArbolNodos.aspx?idNodo=6383. Accessed January 20th 2020"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1008"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30312-3"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/590004"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00071-2"},{"key":"e_1_2_8_16_1","volume-title":"Assessment Report: Cresemba","author":"EMA","year":"2015"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S102207"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0443-1"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3683-2"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1638789"},{"key":"e_1_2_8_21_1","volume-title":"The Cost of Treating Mucormycosis with Isavuconazole Compared with Liposomal Amphotericin B Followed by Posaconazole in Italy: Economic Evaluation Of The Phase III Vital Study and Fungiscope Matched Case\u2010Control Analysis","author":"Bagshaw E","year":"2017"},{"key":"e_1_2_8_22_1","volume-title":"The Cost of Treating Mucormycosis with Isavuconazole Compared with Liposomal Amphotericin B Followed by Posaconazole In Germany: Economic Evaluation of the Phase III Vital Study and Fungiscope Matched Case\u2010Control Analysis","author":"Bagshaw E","year":"2017"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0231"},{"key":"e_1_2_8_24_1","unstructured":"HSCIC.Hospital episode statistics. Admitted patient care England 2016\u20132017. In: Centre HaSCI ed2017."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03908.x"},{"key":"e_1_2_8_27_1","unstructured":"AEMPS\u2010CIMA.Centro de informaci\u00f3n online de medicamentos.2019;https:\/\/cima.aemps.es\/cima\/publico\/home.html. Accessed 20\/02\/2020"},{"key":"e_1_2_8_28_1","unstructured":"2001 Ministerio de Sanidad Consumo y Bienestar Social MSCBS DGSP Talla y peso medio seg\u00fan grupo de edad y sexo"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1164175"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00850.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00944.x"},{"key":"e_1_2_8_32_1","unstructured":"Matched\u2010case analysis of primary mucormycosis patients from isavuconazole study 9766\u2010CL\u20100103\/WSA\u2010CS\u2010003 to patients from Fungiscope Registry Database. In:2014."},{"key":"e_1_2_8_33_1","unstructured":"BotPlus.Consejo General de Colegios Oficiales de Farmac\u00e9uticos 2020;https:\/\/botplusweb.portalfarma.com\/. Accessed 20\/01\/2020 2020."},{"key":"e_1_2_8_34_1","unstructured":"Real Decreto\u2010Ley 8\/2010 20 mayo.2010;https:\/\/www.boe.es\/eli\/es\/rdl\/2010\/05\/20\/8. Accessed 20\/01\/2020."},{"key":"e_1_2_8_35_1","unstructured":"Real Decreto Legislativo 1\/2015 de 24 de julio.2015;https:\/\/www.boe.es\/eli\/es\/rdlg\/2015\/07\/24\/1. Accessed 20\/01\/2020"},{"key":"e_1_2_8_36_1","unstructured":"Orden SCB\/953\/2019 de 13 de septiembre.2019;https:\/\/www.boe.es\/boe\/dias\/2019\/09\/19\/pdfs\/BOE\u2010A\u20102019\u201013312.pdfAccessed 20\/01\/2020"},{"key":"e_1_2_8_37_1","unstructured":"Database of healthcare costs eSalud.http:\/\/www.oblikue.com\/bddcostes\/. Accessed January 20th 2020"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1198-743X.2004.00963.x"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2014.1534"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2018.03.018"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12324"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-010-0244-4"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3633"},{"key":"e_1_2_8_45_1","unstructured":"Terr\u00e9s CRR D.R.Glosario de Farmacoeconom\u00eda.2019;www.healthvalue.org\/Glosario\u2010de\u2010Farmacoeconom\u00eda.pdf"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2019.06.007"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12344"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.13189","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/myc.13189","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.13189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T04:42:17Z","timestamp":1693802537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.13189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/myc.13189"],"URL":"https:\/\/doi.org\/10.1111\/myc.13189","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"2020-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}